fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Nadolol

5 general benefit · 3 not a benefit

Apo-Nadolol · DIN 00782505 · 40 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Nadolol · DIN 00782505 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $0.2375 Health Canada: Marketed since 2020-11-05 · brand APO-NADOLOL · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 40 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Nadolol: Formulary list price $0.24 per unit (the source does not state the unit; exact figure $0.2375). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00782505)

Source record
DIN 00782505: Apo-Nadolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400058; group id 286; item number 0611; lccId None; manufacturer id APX Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2375; ministry $0.2375 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00782505 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9178
Interchangeable products
Corgard · DIN 00607126 · not recorded Mint-Nadolol · DIN 02496380 · $0.2375
Shortage status: shortage reported ended June 25, 2026 (report last updated June 25, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782505
Shortage record checked October 6, 2026

Mint-Nadolol · DIN 02496380 · 40 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mint-Nadolol · DIN 02496380 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-11-30 Daily cost (source): $0.2375 Health Canada: Marketed since 2020-07-21 · brand MINT-NADOLOL · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 40 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Nadolol: Formulary list price $0.24 per unit (the source does not state the unit; exact figure $0.2375). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02496380)

Source record
DIN 02496380: Mint-Nadolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400058; group id 286; item number 0611; lccId None; manufacturer id MIN Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2375; ministry $0.2375 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02496380 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98626
Interchangeable products
Apo-Nadolol · DIN 00782505 · $0.2375 Corgard · DIN 00607126 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02496380
Shortage record checked October 6, 2026

Apo-Nadolol · DIN 00782467 · 80 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Nadolol · DIN 00782467 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $0.6820 Health Canada: Marketed since 2021-02-26 · brand APO-NADOLOL · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 80 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Nadolol: Formulary list price $0.34 per unit (the source does not state the unit; exact figure $0.3410). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00782467)

Source record
DIN 00782467: Apo-Nadolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400042; group id 286; item number 0612; lccId None; manufacturer id APX Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3410; ministry $0.3410 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00782467 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9176
Interchangeable products
Corgard · DIN 00463256 · not recorded Mint-Nadolol · DIN 02496399 · $0.3410
Shortage status: shortage reported ended June 25, 2026 (report last updated June 25, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782467
Shortage record checked October 6, 2026

Mint-Nadolol · DIN 02496399 · 80 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mint-Nadolol · DIN 02496399 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-11-30 Daily cost (source): $0.6820 Health Canada: Marketed since 2020-08-19 · brand MINT-NADOLOL · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 80 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Nadolol: Formulary list price $0.34 per unit (the source does not state the unit; exact figure $0.3410). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02496399)

Source record
DIN 02496399: Mint-Nadolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400042; group id 286; item number 0612; lccId None; manufacturer id MIN Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3410; ministry $0.3410 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02496399 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98627
Interchangeable products
Apo-Nadolol · DIN 00782467 · $0.3410 Corgard · DIN 00463256 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02496399
Shortage record checked October 6, 2026

Apo-Nadolol · DIN 00782475 · 160 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Nadolol · DIN 00782475 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $1.2046 Health Canada: Marketed since 2021-02-26 · brand APO-NADOLOL · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 160 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Nadolol: Formulary list price $1.20 per unit (the source does not state the unit; exact figure $1.2046). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00782475)

Source record
DIN 00782475: Apo-Nadolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400008; group id 286; item number 0613; lccId None; manufacturer id APX Source form: Tab; strength: 160mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.2046; ministry $1.2046 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00782475 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9177
Interchangeable products
Corgard · DIN 00523372 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782475
Shortage record checked October 6, 2026

Corgard · DIN 00607126 · 40 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-05-29 — choose a marketed DIN from the same-category list.Discontinued May 29, 2006 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-05-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-05-29 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Corgard · DIN 00607126 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Daily cost (source): $0.2375 Health Canada: Cancelled post market since 2006-05-29 · brand CORGARD TAB 40MG · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 40 MG · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Corgard: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00607126)

Source record
DIN 00607126: Corgard Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400058; group id 286; item number 0611; lccId None; manufacturer id BQU Source form: Tab; strength: 40mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00607126 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5670
Interchangeable products
Apo-Nadolol · DIN 00782505 · $0.2375 Mint-Nadolol · DIN 02496380 · $0.2375
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00607126
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since May 29, 2006 — choose a marketed DIN from the same-category list.

Corgard · DIN 00463256 · 80 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-10-25 — choose a marketed DIN from the same-category list.Discontinued October 25, 2006 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-10-25 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-10-25 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Corgard · DIN 00463256 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Daily cost (source): $0.6820 Health Canada: Cancelled post market since 2006-10-25 · brand CORGARD TAB 80MG · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 80 MG · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Corgard: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00463256)

Source record
DIN 00463256: Corgard Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400042; group id 286; item number 0612; lccId None; manufacturer id BQU Source form: Tab; strength: 80mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00463256 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3518
Interchangeable products
Apo-Nadolol · DIN 00782467 · $0.3410 Mint-Nadolol · DIN 02496399 · $0.3410
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00463256
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 25, 2006 — choose a marketed DIN from the same-category list.

Corgard · DIN 00523372 · 160 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-10-29 — choose a marketed DIN from the same-category list.Discontinued October 29, 2004 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-10-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2004-10-29 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Corgard · DIN 00523372 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Daily cost (source): $1.2046 Health Canada: Cancelled post market since 2004-10-29 · brand CORGARD TAB 160MG · ATC C07AA12 NADOLOL · form Tablet · route Oral · ingredients NADOLOL 160 MG · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Corgard: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00523372)

Source record
DIN 00523372: Corgard Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400008; group id 286; item number 0613; lccId None; manufacturer id BQU Source form: Tab; strength: 160mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00523372 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4145
Interchangeable products
Apo-Nadolol · DIN 00782475 · $1.2046
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00523372
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 29, 2004 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (C07A, C07AA): coverage varies; not interchangeable

  • Propranolol (Inderal-LA): general benefit, not a benefit
  • Sotalol (Sotacor): general benefit, not a benefit
  • Timolol (Blocadren): general benefit, not a benefit
  • Acebutolol (Sectral): general benefit, not a benefit
  • Atenolol (Apo-Atenol): general benefit
  • Bisoprolol (Sandoz Bisoprolol Tablets): general benefit, not a benefit

3 more in the class list below

Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00 24:04 Cardiac Drugs

PROPRANOLOL

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (8), General benefit (7), Listed, not a benefit (4) · strengths: 60mg, 80mg, 120mg, 160mg, 10mg, 20mg, 40mg · LA Cap, Tab

SOTALOL HCL

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 80mg, 160mg · Tab

TIMOLOL MALEATE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

CARVEDILOL

· 36 products · Listed, not a benefit (4), Limited Use, codes 183 (32) · strengths: 3.125mg, 6.25mg, 12.5mg, 25mg · Tab

NEBIVOLOL HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 59 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS Angina: APO-NADOLOL (nadolol) is indicated for prophylaxis of angina pectoris. Hypertension: APO-NADOLOL is indicated in patients with mild or moderate hypertension. APO-NADOLOL is usually used in combination with other drugs, particularly a thiazide diuretic. However, it may be tried alone as an initial agent in those patients in whom, in the judgment of the physician, treatment should be started with a beta-blocker rather than a diuretic. The combination of nadolol with a diuretic has been found to be compatible and generally more effective than nadolol alone. In a few cases where peripheral vasodilators were used with nadolol, no evidence of incompatibility was seen. APO-NADOLOL is not recommended for the emergency treatment of hypertensive crises. Page 4 of 31 https://pdf.hres.ca/dpd_pm/00057965.PDF PM date: August 27, 2020 Source product: APO-NADOLOL; DIN 00782467; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Nadolol · DIN 00782505 Shortage status: shortage reported ended 2026-06-25 (report last updated 2026-06-25); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782505

Check this DIN again

Apo-Nadolol · DIN 00782467 Shortage status: shortage reported ended 2026-06-25 (report last updated 2026-06-25); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00782467

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Corgard: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026